TAVI is recommended in patients in intermediate risk group in updated Sweden national guideline

04

Sep 2018

At the end of June of 2018, the National Board of Health and Welfare (Socialtyrelsen) has published an updated version of the National clinical guidelines for heart care. The review of the guidelines was conducted in order to include few updated recommendations regarding:

  • the use of medication for the treatment arrhythmia;
  • the use of medical devices for the treatment of valvular heart disease:
    • transcatheter aortic valve implantation (TAVI) should be offered in patients with severe symptomatic aortic stenosis and the following risk profiles:
      • inoperable patients (priority level 3);
      • patients with high surgical risk (priority level 4);
      • patients with intermediate surgical risk (priority level 4).

Three new recommendations in relation to medication for the treatment of coronary heart disease were also provided.

See the summary of all changes in Swedish here.

See full information in Swedish here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

28

Feb 2023

In February 2023, NHS England released the position statement on Transcatheter Aortic Valve Implantation (TAVI) and Surgical Aortic Valve Replacement (SAVR) for symptomatic, severe aortic stenosis in adults to support elective performance. Previously, NHS England was commissioning TAVI at high surgical risk. This new position statement sets criteria for intermediate and low-surgical risk patients who are eligible for TAVI.

Read more

20

Feb 2023

In February 2023, Swedish Medical Technologies Product (MTP) Council announced ongoing horizon scanning within the Orderly introduction framework for medical technologies to be used in benign prostatic hyperplasia. The Dental and Pharmaceutical Benefits Agency (TLV) initiated a theme survey, accepting suggestions until March 31, 2023.

Read more

10

Feb 2023

On January 24, 2023, the Swedish National Board of Health and Welfare recommended introducing a national screening program for spinal muscular atrophy (SMA) in newborns. It will identify children with a homozygous deletion in the SMN1 gene and 1–3 copies of the SMN2 gene. SMA testing must be included in the existing newborn screening (so-called PKU test). The launch of the new screening program is expected in the summer of 2023.

Read more

30

Nov 2022

In November 2022, the National Board of Health and Welfare released the Swedish version of the NordDRG system to come into force in January 2023, including the list of DRG codes, names, and cost-weights. A total of 77 new DRGs will be implemented. Key new DRGs were introduced in cardiovascular, gastrointestinal, and endoscopy fields, also for breast reconstruction and bone-anchored hearing implants.

Read more

25

Nov 2022

In November 2022, Swedish Medical Technologies Product (MTP) Council issued a policy of proven experience for medical technology, which complies profession's assessment of how appropriate medical technology is in specific conditions. The policy provides some examples of how the MTP Council acquires knowledge of proven experience and its impact on the MTP Council's recommendations.

Read more